Harwood Feffer LLP Announces Investigation of Synergetics USA, Inc.

NEW YORK, Sept. 2, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Synergetics USA, Inc. ("Synergetics" or the "Company") (NASDAQ: SURG) concerning the proposed acquisition of the Company by Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX).

Under the terms of the agreement between the companies, Valeant will promptly commence a tender offer to acquire all outstanding shares of Synergetics' common stock for $6.50 per share in cash plus one contingent value right entitling the stockholder to receive up to $1.00 per share if specified sales thresholds for Synergetics are achieved following the closing.

Our investigation concerns whether the Synergetics board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders. 

If you own Synergetics shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

James G. Flynn, Esq.

Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: jflynn@hfesq.com
Website: http://www.hfesq.com 
Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

SOURCE Harwood Feffer LLP